Skip to main content
Fig. 6 | BMC Neurology

Fig. 6

From: Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis

Fig. 6

Random-effect model of trial sequential analysis for changes in monthly migraine days. The dashed red lines represent the trial sequential monitoring boundary (upper O’Brien Fleming with α = 5%, β = 20%, low risk of bias). Required information size (RIS) of 506 participants were calculated. Complete blue line represents cumulative Z-curve, which is well past the RIS needed. Cumulative Z-curve cross conventional boundary (complete red line) and the trial sequential monitoring boundary (dashed red line)

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us